ClinicalTrials.gg
CompletedNCT06928051Updated Sep 21, 2026

A Study of S-892216 in Participants With COVID-19

A Phase 2 interventional study of S-892216 and Placebo in COVID-19, sponsored by Shionogi. Completed at 57 sites in 2 countries. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-09-21.

Sponsored by Shionogi · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2025, 1 year 1 month ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Sep 2026.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
282
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 75 studies in COVID-19 with a site in Japan — 10 open to participants now, 11 under way, 8 of them phase 3. COVID-19 · Japan.

Enrollment
37th of 59
282 · median 602
Started
2025
with 1 other
Phase 2
5 of 75
none open now
Registered
71st of 75
by date
Lead sponsor
5 of 75
Shionogi

Among the 75 studies in COVID-19 with a site in Japan, this one is the 37th largest by enrollment of the 59 interventional ones that give a count, is one of 2 that started in 2025, is one of 5 in phase 2, and was the 71st registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

10 of the 75 studies in COVID-19 with a site in Japan are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies in COVID-19 with a site in Japan, or all of them as a file.
02

Study summary

The primary objective of this study is to investigate the antiviral effect of S-892216 in participants with coronavirus disease 2019 (COVID-19) due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

03

Conditions studied

  • COVID-19

Browse trials for

Keywords

  • S-892216
  • Mpro
  • Main Protease
  • Nonstructural Protein 5
  • nsp5
  • Protease Inhibitor
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Must weigh ≥40 kilograms
  • Must have at least 2 COVID-19 signs/symptoms of mild or higher severity, or at least 1 sign/symptom of moderate or higher severity, within the 72 hours prior to randomization, and the symptoms must still be present in the 24 hours prior to randomization
  • Documentation of laboratory-confirmed active SARS-CoV-2 infection, as determined by a nucleic acid (for example, qRT-PCR) or antigen test from any respiratory tract specimen (for example, oropharyngeal, NP or nasal swab, or saliva), or any other SARS-CoV-2 test approved according to local regulations, collected ≤72 hours (3 days) prior to randomization
  • Oxygen saturation (SpO2) of ≥92% on room air adjusted for altitude and obtained at rest by study staff within the 24 hours prior to randomization. For a potential participant who regularly receives chronic supplementary oxygen for an underlying lung condition, SpO2 measured while on standard home oxygen supplementation level must be ≥92%.
  • Capable and willing to complete an electronic participant diary
  • use by female participants should be consistent with local regulations regarding the use of contraceptive methods for those participating in clinical studies. Note: The medication may lead to an increase or decrease of sex hormone levels; therefore, hormonal contraception must not be used alone and must be combined with a barrier method.
  • A woman of must have a negative urine pregnancy test within the 24 hours before the first dose of investigational intervention
  • Must be randomized ≤72 hours from onset of COVID-19 symptoms (defined as the time point when at least 1 of the COVID-19 symptoms occurs)
  • Agrees to not participate in another clinical trial for the treatment of COVID-19 or SARS-CoV-2 during the study period unless meeting hospitalization criteria or reaching Day 28, whichever is earliest

Key Exclusion Criteria:

  • High risk of progression to severe COVID-19, as defined in the protocol
  • Documented respiratory infection (for example, influenza, respiratory syncytial virus) other than COVID-19 within the 14 days prior to the screening visit
  • Known current renal impairment defined as estimated \<60 milliliters/minute/1.73 meters squared or requiring dialysis
  • Known history of cirrhosis or liver decompensation (including ascites, variceal bleeding, or hepatic encephalopathy)
  • Known history of any of the following abnormalities in the following clinical laboratory tests (within the 6 months prior to the screening visit):

    • Total ≥2 × (ULN) (except for Gilbert's syndrome)
    • or alanine aminotransferase ≥2 × ULN
  • A corrected using Fridericia's formula at the screening visit:

    • For males: >450 milliseconds (msec)
    • For females: >470 msec
  • History of hospitalization for the current SARS-CoV-2 infection or anticipated need for hospitalization within 24 hours after randomization
  • History of cancer except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of disease for 3 years
  • Women with a history of osteoporosis
  • Received or expected to receive any dose of a SARS-CoV-2 vaccine within 14 days of randomization or during the study through day 28
  • Received or expected to receive any other COVID-19-specific treatment, including outpatient remdesivir, Paxlovid, molnupiravir, monoclonal antibodies, ensitrelvir, and convalescent plasma for the current COVID-19 infection
  • Exposed to an investigational drug within 30 days or 5 half-lives of the drug prior to the screening visit

Note: Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
282 participants (actual)

Study arms

  • Experimental
    S-892216: Dose 1

    Participants will receive S-892216.

    Drug: S-892216 · Drug: Placebo

  • Experimental
    S-892216: Dose 2

    Participants will receive S-892216.

    Drug: S-892216

  • Experimental
    S-892216: Dose 3

    Participants will receive S-892216.

    Drug: S-892216

  • Placebo comparator
    Placebo

    Participants will receive placebo.

    Drug: Placebo

Interventions

  • S-892216 will be administered orally as a tablet.

  • DrugPlacebo

    Placebo will be administered orally as a tablet.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in SARS-CoV-2 Viral RNA Level on Day 4 as Assessed by Quantitative Reverse-transcription Polymerase Chain Reaction (qRT-PCR) of Nasopharyngeal (NP) Swabs

    Time frame: Baseline through Day 4

Secondary outcomes

  1. Time to the First Negative SARS CoV-2 Viral RNA qRT-PCR Result

    Time frame: Baseline through Day 28

  2. Time to the First SARS CoV-2 Viral RNA Viral RNA Level Less Than the Lower Limit of Quantitation (LLOQ)

    Time frame: Baseline through Day 28

  3. Number of Participants With a Positive SARS CoV-2 Viral RNA qRT-PCR Test

    Time frame: Baseline, Days 2, 4, 6, 10, 14, 21, and 28

  4. Change From Baseline in SARS CoV-2 Viral RNA Level

    Time frame: Baseline, Days 2, 6, 10, 14, 21, and 28

  5. Area Under the Curve of Change From Baseline in SARS-CoV-2 Viral RNA Level Through Day 4 and Day 6

    Time frame: Baseline through Day 4 and Day 6

  6. Time to Sustained (2 Consecutive Days) Resolution of COVID-19 Symptoms

    Time frame: Baseline through Day 28

  7. Time to First Resolution of COVID-19 Symptoms

    Time frame: Baseline through Day 28

  8. Time to Return to Pre-COVID-19 Health

    Time frame: Baseline through Day 28

  9. Plasma Concentration of S-892216

    Time frame: Days 2, 6, and 10

07

Study locations

57 sites
  • Healthstar Research
    Hot Springs, Arkansas 71913, United States
  • Invictus Clinical Research Group LLC
    Coconut Creek, Florida 33073, United States
  • Hope Clinical Trials
    Coral Gables, Florida 33134, United States
  • Advanced Research for Health Improvement LLC
    Immokalee, Florida 34142, United States
  • LCC Medical Research
    Miami, Florida 33126, United States
  • CCM Clinical Research Group
    Miami, Florida 33133, United States
  • Global Health Clinical Trials
    Miami, Florida 33135, United States
  • Continental Clinical Research
    Miami, Florida 33144, United States
  • Entrust Clinical Research
    Miami, Florida 33176, United States
  • Kendall South Medical Center Inc
    Miami, Florida 33185, United States
  • Palm Springs Community Health Center
    Miami Lakes, Florida 33014, United States
  • Quality Research of South Florida
    Miami Lakes, Florida 33016, United States
  • Oceane7 Medical & Research Center, Inc.
    Miami Lakes, Florida 33144, United States
  • Combined Research Orlando Phase I-IV LLC
    Orlando, Florida 32807, United States
  • Global Clinical Professionals
    St. Petersburg, Florida 33705, United States
  • Balanced Life Health Care Solutions
    Lawrenceville, Georgia 30046, United States
  • PanAmerican Clincal Research
    Brownsville, Texas 78520, United States
  • Alina Clinical Trials LLC
    Dallas, Texas 75209, United States
  • Care United Research, LLC
    Forney, Texas 75126, United States
  • Clinical Research Partners LLC
    Richmond, Virginia 23226, United States
  • Frontier Clinical Research LLC
    Kingwood, West Virginia 26537, United States
  • Japanese Site 10
    Multiple Locations, Japan
  • Japanese Site 11
    Multiple Locations, Japan
  • Japanese Site 12
    Multiple Locations, Japan
  • Japanese Site 13
    Multiple Locations, Japan
  • Japanese Site 14
    Multiple Locations, Japan
  • Japanese Site 15
    Multiple Locations, Japan
  • Japanese Site 16
    Multiple Locations, Japan
  • Japanese Site 17
    Multiple Locations, Japan
  • Japanese Site 18
    Multiple Locations, Japan
  • Japanese Site 19
    Multiple Locations, Japan
  • Japanese Site 1
    Multiple Locations, Japan
  • Japanese Site 20
    Multiple Locations, Japan
  • Japanese Site 21
    Multiple Locations, Japan
  • Japanese Site 22
    Multiple Locations, Japan
  • Japanese Site 23
    Multiple Locations, Japan
  • Japanese Site 24
    Multiple Locations, Japan
  • Japanese Site 25
    Multiple Locations, Japan
  • Japanese Site 26
    Multiple Locations, Japan
  • Japanese Site 27
    Multiple Locations, Japan
  • Japanese Site 28
    Multiple Locations, Japan
  • Japanese Site 29
    Multiple Locations, Japan
  • Japanese Site 2
    Multiple Locations, Japan
  • Japanese Site 30
    Multiple Locations, Japan
  • Japanese Site 31
    Multiple Locations, Japan
  • Japanese Site 32
    Multiple Locations, Japan
  • Japanese Site 33
    Multiple Locations, Japan
  • Japanese Site 34
    Multiple Locations, Japan
  • Japanese Site 35
    Multiple Locations, Japan
  • Japanese Site 36
    Multiple Locations, Japan
  • Japanese Site 3
    Multiple Locations, Japan
  • Japanese Site 4
    Multiple Locations, Japan
  • Japanese Site 5
    Multiple Locations, Japan
  • Japanese Site 6
    Multiple Locations, Japan
  • Japanese Site 7
    Multiple Locations, Japan
  • Japanese Site 8
    Multiple Locations, Japan
  • Japanese Site 9
    Multiple Locations, Japan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2025 to primary completion in Sep 2025, 3 months.

Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 13. This study's 3 months is below that.

Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2025
First posted
Apr 15, 2025
StartActual
Jun 6, 2025
Primary completionActual
Sep 22, 2025
CompletionActual
Sep 22, 2025
Results delay requested
Sep 17, 2026
Last update
Sep 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06928051
Lead sponsor
Shionogi
Responsible party
Sponsor
First posted
Apr 15, 2025
Start date
Jun 6, 2025
Primary completion
Sep 22, 2025
Completion
Sep 22, 2025
Last update
Sep 21, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: S-892216

Start the discussion